Procaryotic Micro-organism Patents (Class 435/71.2)
-
Patent number: 6413510Abstract: The invention relates to the method of preventing and treating sepsis using chemokines selected from mature or modified KC [SEQ ID NO: 1], gro&agr;[SEQ ID NO:2], gro&bgr;[SEQ ID NO: 3] or gro&ggr;[SEQ ID NO: 4] or multimers thereof, alone or in conjunction with an anti-infective agent. This invention also relates to a new gro&bgr; dimer chemokine.Type: GrantFiled: February 25, 2000Date of Patent: July 2, 2002Assignee: SmithKline Beecham CorporationInventors: Peter Lawrence DeMarsh, Kyung Oh Johanson
-
Patent number: 6410686Abstract: The present invention provides a novel galanin receptor protein, the GalR2 receptor. Also provided are the nucleic acid sequences encoding this novel receptor protein as well as methods for using this protein and its nucleic acid sequence, and methods useful for developing and identifying compounds for the treatment of diseases and disorders in which galanin is implicated. The importance of this discovery is manifested in the effects of galanin, which include antinociceptive activity, smooth muscle contraction, cardiovascular activity, pituitary hormone release, cognition, and increased food intake. Thus, this receptor protein is useful for screening for galanin agonist and antagonist activity for controlling these conditions.Type: GrantFiled: June 5, 1996Date of Patent: June 25, 2002Assignee: Bayer CorporationInventors: Brian T. Bloomquist, Michael L. McCaleb, Linda J. Cornfield, Heeja Yoo-Warren
-
Patent number: 6410008Abstract: Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.Type: GrantFiled: December 12, 1994Date of Patent: June 25, 2002Assignee: Beth Israel Hospital AssociationInventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
-
Patent number: 6410263Abstract: The invention provides histidine kinase polypeptides and polynucleotides encoding histidine kinase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing histidine kinase polypeptides to screen for antibacterial compounds.Type: GrantFiled: January 29, 1998Date of Patent: June 25, 2002Assignees: Smithkline Beecham Corporation, Smithkline Beecham p.l.c.Inventors: Nicola Gail Wallis, Lisa Kathleen Shilling, Richard Lloyd Warren
-
Patent number: 6410708Abstract: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer, and nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing such antigens PRO301, PRO362 or PRO245.Type: GrantFiled: March 5, 1999Date of Patent: June 25, 2002Assignee: Genentech, Inc.Inventors: Avi Ashkenazi, Sherman Fong, Audrey Goddard, Austin L. Gurney, Mary A. Napier, Daniel Tumas, William I. Wood
-
Patent number: 6410706Abstract: The present invention provides a novel receptor kinase and the gene thereof which can be used for activating plant defense systems against several pathogens such as fungi. The receptor kinase CHRK1 of this present invention has an extracellular domain similar to a chitinase, and whose gene expression is stimulated by infection of TMV. In addition, the receptor kinase CHRK1 contains a chitin-binding activity as well as a kinase activity so that it binds to chitin of fungal cell wall as a chitin receptor, stimulates a kinase domain, and thus effectively activates versatile plant defense systems. Therefore, the receptor kinase CHRK1 of this present invention can be used for developing plants having high resistance to fungi.Type: GrantFiled: February 14, 2000Date of Patent: June 25, 2002Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Hyun-Sook Pai, Jang-Ryol Liu, Hye-Sun Cho, Youn-Sung Kim
-
Patent number: 6407222Abstract: The dog GnRH receptor has been isolated, cloned and sequenced. The dog GnRH receptor may be used to screen and identify compounds which bind to the GnRH receptor. Such identified compounds may be used in the treatment of sex hormone related conditions such as endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasias such as cancers of the prostate, breast and ovary, gonadotrophe pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome and benign prostatic hypertrophy. The receptor proteins and polypeptides, nucleic acids, cells and assays of this invention are useful in drug screening and development, diagnosis and therapeutic applications.Type: GrantFiled: May 31, 2000Date of Patent: June 18, 2002Assignee: Merck & Co., Inc.Inventors: Jisong Cui, Jane-Ling Lo, George R. Mount
-
Patent number: 6403782Abstract: Disclosed is substantially pure eotaxin DNA sequence and eotaxin polypeptide, and methods of using such DNA and polypeptide to direct chemotaxis of eosinophils. Methods are provided for the treatment diseases and disorders such as inflammation and tumorigenesis.Type: GrantFiled: August 4, 1999Date of Patent: June 11, 2002Assignees: President and Fellows of Harvard College, The General Hospital CorporationInventors: Andrew D. Luster, Philip Leder, Marc Rothenberg, Eduardo Garcia
-
Patent number: 6403334Abstract: The invention provides gidB polypeptides and DNA (RNA) encoding gidB polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing gidB polypeptides to screen for antibacterial compounds.Type: GrantFiled: December 16, 1998Date of Patent: June 11, 2002Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.Inventor: Howard Kallender
-
Patent number: 6399761Abstract: Methods for isolating K+Hnov genes are provided. The K+Hnov nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.Type: GrantFiled: June 18, 1999Date of Patent: June 4, 2002Assignee: ICAgen, Inc.Inventors: Andrew P. Miller, Ping Hu, Mark Edward Curran, Marc Rutter, Wang Jiang-Yang
-
Publication number: 20020064835Abstract: The invention is directed to methods for purifying Troponin I, particularly recombinant Tropnin I produced in a bacterial expression system. Recombinant Tropnin I can be advantageously purified after reversibly protecting the free sulfhydryl groups, e.g., by forming sulfates. In a specific example, Tropnin I reacted with sodium tetrafhionate yielded sulfitolyzed Tropnin I, which was purified by chromatography on an anion exchanger, followed by hydrophobic interaction chromatography. Facile deprotection of the sulfhydryl groups yields a highly purified product ready for refolding.Type: ApplicationFiled: July 10, 2001Publication date: May 30, 2002Applicant: Diosynth RTP, Inc.Inventors: Gregory Conn, Brian Reardon, Xianfang Zeng, Chenming Zhang
-
Patent number: 6395514Abstract: The present invention relates to a novel CK&agr;-5 protein which is a member of the alpha chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CK&agr;-5 protein. CK&agr;-5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CK&agr;-5 activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: GrantFiled: November 18, 1998Date of Patent: May 28, 2002Assignee: Human Genome Sciences, Inc.Inventors: Ying-Fei Wei, Yi Li, Jian Ni, Craig A. Rosen, Steven M. Ruben
-
Patent number: 6391589Abstract: Human chemokine Beta-10 polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.Type: GrantFiled: January 7, 2000Date of Patent: May 21, 2002Assignees: Human Genome Sciences, Inc., SmithKline Beecham, Corp.Inventors: Henrik S. Olsen, Haodong Li, Mark D. Adams, Solange H. L. Gentz, Ralph Alderson, Yuling Li, David Parmelee, John R. White, Edward R. Appelbaum
-
Patent number: 6383781Abstract: A method is provided for producing a polypeptide of interest by (a) cultivating a mutant of a parent Aspergillus cell, wherein (i) the mutant comprises a first nucleic acid sequence encoding the polypeptide and a second nucleic acid sequence comprising a modification of at least one of the genes responsible for the biosynthesis or secretion of at least one toxin, and (ii) the mutant produces less of the toxin than the parent Aspergillus cell when cultured under the same conditions; and (b) isolating the polypeptide from the culture medium. Also, mutants of Aspergillus cells are provided, as well as methods for obtaining the mutant cells.Type: GrantFiled: December 23, 1999Date of Patent: May 7, 2002Assignee: Novozymes A/SInventors: Bjorn Eggert Christensen, Henrik Mollgaard, Svend Kaasgaard, Jan Lehmbeck
-
Patent number: 6380375Abstract: The monkey GnRH receptor has been isolated, cloned and sequenced. The monkey GnRH receptor may be used to screen and identify compounds which bind to the GnRH receptor. Such identified compounds may be used in the treatment of sex hormone related conditions such as endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasias such as cancers of the prostate, breast and ovary, gonadotrophe pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome and benign prostatic hypertrophy. The receptor proteins and polypeptides, nucleic acids, cells and assays of this invention are useful in drug screening and development, diagnosis and therapeutic applications.Type: GrantFiled: February 10, 2000Date of Patent: April 30, 2002Assignee: Merck & Co., Inc.Inventors: Jisong Cui, Jane-Ling Lo, George R. Mount
-
Patent number: 6376190Abstract: This invention is directed towards a method for obtaining nucleic acid ligands against target proteins without directly purifying the target proteins. The method used in the invention is called SELEX, which is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which the targets proteins play a causative role.Type: GrantFiled: September 22, 2000Date of Patent: April 23, 2002Assignee: SomaLogic, Inc.Inventors: Larry Gold, Dominic A. Zichi, Jonathan Drew Smith
-
Patent number: 6372454Abstract: The present invention relates to a novel follistatin-3 protein which is a member of the family of inhibin-related proteins. In particular, isolated nucleic acid molecules are provided encoding the human follistatin-3 protein. Follistatin-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of follistatin-3 activity. Also provided are diagnostic methods for detecting reproductive system-related disorders and disorders of the regulation of cell growth and differentiation and therapeutic methods for treating reproductive system-related disorders and disorders of the regulation of cell growth and differentiation.Type: GrantFiled: August 27, 1998Date of Patent: April 16, 2002Assignee: Human Genome Sciences, Inc.Inventors: D. Roxanne Duan, Steven M. Ruben
-
Patent number: 6372456Abstract: The present invention relates to a novel CK(&agr;-6 protein which is a member of the alpha chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CK&agr;-6 protein. CK&agr;-6 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CK&agr;-6 activity. Also provided are diagnostic methods for detecting CNS and immune system-related disorders and therapeutic methods for treating CNS and immune system-related disorders.Type: GrantFiled: October 23, 1998Date of Patent: April 16, 2002Assignee: Human Genome Sciences, Inc.Inventors: Ying-Fei Wei, Steven M. Ruben, Craig A. Rosen
-
Patent number: 6365158Abstract: The present invention includes methods for generating neutralizing antitoxin directed against clostridial toxins. In particular, the antitoxin directed against these toxins is produced in avian species using soluble recombinant clostridial toxin proteins. This avian antitoxin is designed so as to be orally administrable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution). These antitoxins are useful in the treatment of humans and other animals intoxicated with at least one bacterial toxin.Type: GrantFiled: October 23, 1997Date of Patent: April 2, 2002Assignee: Promega CorporationInventors: James A. Williams, John A. Kink
-
Patent number: 6365370Abstract: DNA encoding human 5-HT3-C has been cloned and characterized. The recombinant protein is capable of forming biologically active human 5-HT3-C protein. The cDNA has been expressed in recombinant host cells that produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: GrantFiled: September 1, 1999Date of Patent: April 2, 2002Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Adrienne E. Dubin, Mark G. Erlander, Arne Huvar, Rene Huvar, Lukas K. Buehler
-
Patent number: 6362316Abstract: In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtype mGluR6, and the proteins encoded thereby. In addition to being useful for the production of metabotropic glutamate receptor subtype mGluR6, nucleic acids of the invention are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing a novel metabotropic glutamate receptor subtype, mGluR6, the present invention also comprises methods for using the invention receptor subtype to identify and characterize compounds which affect the function of such receptor subtype, e.g., agonists, antagonists, and modulators of glutamate receptor function.Type: GrantFiled: March 26, 1999Date of Patent: March 26, 2002Assignee: Merck & Co., Inc.Inventors: Lorrie P. Daggett, Chin-Chun Lu
-
Patent number: 6358706Abstract: A DNA molecule encoding a novel isoform of the human T-type low voltage activated calcium channel (alpha1G-c) has been cloned and characterized. The biological and structural properties of this protein is disclosed, as is the amino acid and nucleotide sequence.Type: GrantFiled: October 26, 1999Date of Patent: March 19, 2002Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Adrienne E. Dubin, Jose E. Galindo, Jayashree Pyati, Jessica Y. Zhu, Mark G. Erlander
-
Patent number: 6358718Abstract: The present invention provides methods for stabilizing proteins, preventing protein aggregation, renaturation of previously-denatured proteins, reactivating a protein that has been inactivated by denaturation, preserving enzyme activities under conditions of elevated temperatures, inducing thermotolerance in bacteria, increasing the temperature optimum for the activity of an enzyme, and preventing formation of inclusion bodies by bacterially-expressed recombinant proteins.Type: GrantFiled: March 30, 2000Date of Patent: March 19, 2002Assignee: The University of Mississippi Medical CenterInventors: Mark Olson, Atilla Szebeni
-
Publication number: 20020031807Abstract: The present invention relates to the identification of novel cysteine proteases in Gram-positive microorganisms. The present invention provides the nucleic acid and amino acid sequences for the Bacillus subtilis cysteine proteases CP1, CP2 and CP3. The present invention also provides host cells having a mutation or deletion of part or all of the gene encoding CP1, CP2 or CP3. The present invention also provides host cells further comprising nucleic acid encoding desired heterologous proteins such as enzymes. The present invention also provides a cleaning composition comprising a cysteine protease of the present invention.Type: ApplicationFiled: January 13, 2000Publication date: March 14, 2002Inventor: DAVID A. ESTELL
-
Patent number: 6350855Abstract: Polynucleotides encoding the human IL-11 receptor and fragments thereof are disclosed. IL-11 receptor proteins, methods for their production, inhibitors of binding of human IL-11 and its receptor and methods for their identification are also disclosed.Type: GrantFiled: September 15, 1997Date of Patent: February 26, 2002Assignee: Genetics Institute, Inc.Inventor: James Tobin
-
Patent number: 6348576Abstract: The invention provides a human cornichon protein (CORN) and polynucleotides which identify and encode CORN. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of CORN.Type: GrantFiled: August 2, 1999Date of Patent: February 19, 2002Assignee: Incyte Genomics, Inc.Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah
-
Patent number: 6348321Abstract: A family of fatty acid transport proteins (FATPS) mediate transport of long chain fatty acids (LCFAs) across cell membranes into cells. These proteins exhibit different expression patterns among the organs of mammals. Nucleic acids encoding FATPs of this family, vectors comprising these nucleic acids, as well as the production of FATP proteins in host cells are described. Also described are methods to test FATPs for fatty acid transport function, and methods to identify inhibitors or enhancers of transport function. The altering of LCFA uptake by administering to the mammal an inhibitor or enhancer of FATP transport function of a FATP in the small intestine can decrease or increase calories available as fats, and can decrease or increase circulating fatty acids. The organ specificity of FATP distribution can be exploited in methods to direct drugs, diagnostic indicators and so forth to an organ such as the heart.Type: GrantFiled: January 14, 1999Date of Patent: February 19, 2002Assignees: Whitehead Institute for Biomedical Research, Millennium Pharaceuticals, Inc.Inventors: Andreas Stahl, David J. Hirsch, Harvey F. Lodish, Ruth E. Gimeno, Louis A. Tartaglia
-
Patent number: 6348191Abstract: IL-6 is produced via recombinant DNA techniques. The peptide is useful in the treatment of disorders characterized by deficiencies in hematopoietic cells and in combination with other hematopoietins in cancer therapies.Type: GrantFiled: June 17, 1991Date of Patent: February 19, 2002Assignee: Genetics Institute, Inc.Inventors: Steven C. Clark, Gordon G. Wong, Paul Schendel, John McCoy
-
Publication number: 20020018774Abstract: The present invention relates to enzymes involved in capping of fungal mRNAs, and molecules that inhibit such enzymes. In particular, the invention relates to the novel C. albicans capping enzyme genes ABD1 and CET1 and their encoded protein products, as well as derivatives and analogs thereof. The invention also relates to methods of using of fungal capping enzymes to screen for fungal inhibitors.Type: ApplicationFiled: December 17, 1998Publication date: February 14, 2002Inventors: SIMON GREEN, GARY DALLMANN, MAGDELEINE HUNG, JULIE LANE, CHARLES M. MOEHLE
-
Patent number: 6346394Abstract: Disclosed is a recombinant thermostable enzyme which has a molecular weight of about 54,000-64,000 daltons and a pI of about 5.6-6.6, and releases trehalose from non-reducing saccharides having a trehalose structure as an end unit and a degree of glucose polymerization of at least 3. The enzyme has a satisfactorily-high thermostability, i.e. it is not substantially inactivated even when incubated in an aqueous solution (pH 7.0) at 85° C. for 60 min, and this facilitates the production of trehalose on an industrial scale and in a satisfactorily-high yield.Type: GrantFiled: April 6, 1998Date of Patent: February 12, 2002Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Hitoshi Mitsuzumi, Michio Kubota, Toshiyuki Sugimoto
-
Patent number: 6344552Abstract: Methods and compositions for the prevention and diagnosis of Lyme disease. OspA and OspB polypeptides and serotypic variants thereof, which elicit in a treated animal the formation of an immune response which is effective to treat or protect against Lyme disease as caused by infection with Borrelia burgdorferi. Anti-OspA and anti-OspB antibodies that are effective to treat or protect against Lyme disease as caused by infection with B. burgdorferi. A screening method for the selection of those OspA and OspB polypeptides and anti-OspA and anti-OspB antibodies that are useful for the prevention and detection of Lyme disease. Diagnostic kits including OspA and OspB polypeptides or antibodies directed against such polypeptides.Type: GrantFiled: May 31, 1995Date of Patent: February 5, 2002Assignee: Yale UniversityInventors: Richard A. Flavell, Fred S. Kantor, Stephen W. Barthold, Erol Fikrig
-
Patent number: 6338844Abstract: A nucleic acid with which expression of a polypeptide having interleukin-16 activity can be achieved or regulated in a prokaryotic or eukaryotic host cell, wherein in the region coding for the polypeptide, the nucleic acid (1) corresponds to the DNA sequence SEQ ID NOS:1 and 5-7 or its complementary strand; (b) hybridizes under stringent conditions with the DNA of sequence SEQ ID NOS:1 and 5-7; (c) or is a nucleic acid sequence which, if there was no degeneracy of the genetic code, would hybridize under stringent conditions with the nucleic acid sequences defined by (a) and (b); (d) and, if it codes for a polypeptide having interleukin-16 activity, is suitable as genomic DNA for the recombinant production of IL-16 in eukaryotic host cells and processes for producing the same and pharmaceutical compositions containing the same.Type: GrantFiled: May 11, 1999Date of Patent: January 15, 2002Assignee: Bundesrepublik Deutschland vertreten durch de Bundesminister für GesundheitInventors: Reinhard Kurth, Michael Baier, Norbert Bannert, Karin Metzner, Albrecht Werner
-
Patent number: 6337208Abstract: The present invention relates to cloning vectors, cloning methods and cloning kits. More particularly, the present invention relates to a cloning vector comprising a nucleic acid sequence encoding a polypeptide which when expressed is lethal for a bacterial host cell and at least one cloning site wherein the insertion of a foreign nucleic acid insert in the cloning site causes a disruption of the expression of the lethal polypeptide.Type: GrantFiled: January 3, 2000Date of Patent: January 8, 2002Inventor: Stefan Graupner
-
Patent number: 6335167Abstract: Disclosed are new methods comprising the use of in situ hybridization to detect abnormal nucleic acid sequence copy numbers in one or more genomes wherein repetitive sequences that bind to multiple loci in a reference chromosome spread are either substantially removed and/or their hybridization signals suppressed. The invention termed Comparative Genomic Hybridization (CGH) provides for methods of determining the relative number of copies of nucleic acid sequences in one or more subject genomes or portions thereof (for example, a tumor cell) as a function of the location of those sequences in a reference genome (for example, a normal human genome). The intensity(ies) of the signals from each labeled subject nucleic acid and/or the differences in the ratios between different signals from the labeled subject nucleic acid sequences are compared to determine the relative copy numbers of the nucleic acid sequences in the one or more subject genomes as a function of position along the reference chromosome spread.Type: GrantFiled: May 14, 1999Date of Patent: January 1, 2002Assignee: The Regents of the University of CaliforniaInventors: Daniel Pinkel, Joe W. Gray, Anne Kallioniemi, Ollie-Pekka Kallioniemi, Frederic Waldman, Masaru Sakamoto
-
Patent number: 6333175Abstract: The invention concerns a process for increasing the formation of the natural protein conformation when disulfide-bonded proteins are secreted by a prokaryotic host organism that contains a recombinant DNA coding for the secreted protein whereby the host organism is cultured in a suitable culture medium under suitable conditions for the expression of the recombinant DNA, which is characterized in that a culture medium containing 0.1 to 20 mmol/l of one or several thiol reagents is used.Type: GrantFiled: July 27, 1993Date of Patent: December 25, 2001Assignee: Roche Diagnostics GmbHInventors: Rudolf Glockshuber, Martina Wunderlich, Arne Skerra, Rainer Rudolph
-
Patent number: 6333176Abstract: A plant peptide amidase from the flavedo of oranges is known; this can be obtained only in small quantities and is seasonal. The proposed new enzymes are microbial peptide amidases which can be obtained from micro-organisms recovered from soil samples in a “double screening” and grown. These microbial peptide amidases are particularly useful for (a) the production of peptides and N-terminal-protected amino acids, (b) racemate splitting of N-protected amino acid amides, (c) obtaining non-proteinogenous D-amino acids, and (d) obtaining new N&agr;-protected D-amino acid amides.Type: GrantFiled: August 25, 1999Date of Patent: December 25, 2001Assignee: Degussa AktiengesellschaftInventors: Ursula Stelkes-Ritter, Maria-Regina Kula, Klaudia Wyzgol, Andreas Bommarius, Michael Schwarm, Karlheinz Drauz
-
Patent number: 6331415Abstract: The invention relates to processes for producing an immunoglobulin or an immunologically functional immunoglobulin fragment containing at least the variable domains of the immunoglobulin heavy and light chains. The processes can use one or more vectors which produce both the heavy and light chains or fragments thereof in a single cell. The invention also relates to the vectors used to produce the immunoglobulin or fragment, and to cells transformed with the vectors.Type: GrantFiled: June 10, 1988Date of Patent: December 18, 2001Assignee: Genentech, Inc.Inventors: Shmuel Cabilly, Herbert L. Heyneker, William E. Holmes, Arthur D. Riggs, Ronald B. Wetzel
-
Patent number: 6329517Abstract: The present invention relates to a dermatomyositis-specific auto-antigen, a DNA encoding it and a process for the preparation thereof as well as its use.Type: GrantFiled: January 12, 1998Date of Patent: December 11, 2001Assignee: Privates Institut für Imonologie und Molekulargenetik GmbHInventors: Hans Peter Seelig, Manfred Renz
-
Patent number: 6329174Abstract: The present invention is directed to a nucleic acid encoding a lepidopteran glutamate-gated chloride channel. Vectors and host cells comprising the nucleic acid are also provided. A method of identifying agents that modulate the activity of a lepidopteran glutamate-gated chloride channel is also provided. Such agents are useful as insecticides.Type: GrantFiled: June 13, 2000Date of Patent: December 11, 2001Assignee: Aventis Cropscience SAInventors: Xiao-Zhuo Michelle Wang, Xavier Georges Sarda, Michael David Tomalski, Vincent Paul Mary Wingate
-
Patent number: 6319503Abstract: Disclosed are epitope-containing heat shock fusion proteins, DNA constructs encoding such fusion proteins, and methods of use. More specifically, disclosed are ubiquitin fusion proteins comprising ubiquitin fused to a plurality of identical or non-identical epitopes at specified locations.Type: GrantFiled: February 19, 1998Date of Patent: November 20, 2001Assignee: Proteinix CompanyInventors: John H. Kenten, Alfonso Tramontano, Aprile L. Pilon, Gerald L. Lohnas, Steven F. Roberts
-
Patent number: 6309861Abstract: A process produces a water-soluble, naturally folded eukaryotic polypeptide containing two or several cysteines linked by disulfide bridges. This process involves culturing prokaryotic cells, a) in which the prokaryotic cells contain an expression vector which encodes the polypeptide which contains a prokaryotic signal sequence at the N-terminus, b) under conditions under which the polypeptide is secreted into the periplasm or the medium, c) cleaving the signal sequence and isolating the polypeptide from the periplasm or the medium. In this process, the culturing is carried out in the presence of arginine or a compound of the formula I R2—CO—NR1 (I) in which R and R1 represent hydrogen or a saturated or unsaturated branched or unbranched C1-C4 alkyl chain and R2 represents hydrogen, NHR1 or a saturated or unsaturated branched or unbranched C1-C3 alkyl chain, is suitable for the recombinant production of polypeptides in prokaryotes in a high yield.Type: GrantFiled: April 20, 2000Date of Patent: October 30, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Dorothee Ambrosius, Rainer Rudolph, Joerg Schaeffner, Elisabeth Schwarz
-
Patent number: 6306404Abstract: The invention pertains to adjuvant and vaccine compositions of monophosphoryl lipid A, sugar and optionally an amine based surfactant, which when frozen and thawed or lyophilized and reconstituted reform a colloidal suspension having a light transmission of greater than or equal to 88% as measured spectrophotometrically.Type: GrantFiled: July 13, 1999Date of Patent: October 23, 2001Assignee: American Cyanamid CompanyInventors: Vincent James LaPosta, John Hayward Eldridge
-
Patent number: 6303357Abstract: This invention provides an L-&agr;-glycerophosphate oxidase (GPO) having excellent properties such as stability, heat resistance and reactivity. A recombinant GPO obtained by replacing an amino acid of a specified position of an amino acid sequence deduced from the Enterococcus faecium No. 7044 GPO gene or DNA coding for the GPO with other amino acid has excellent thermal stability and reactivity. That is, the invention provides modified forms of the GPO having the amino acid sequence of Sequence No. 1 in the Sequence Listing, in which the 130-position leucine counting from the N-terminus of the GPO is replaced by other amino acid and/or the 225-position serine counting from the N-terminus of the GPO is replaced by other amino acid and/or the 298-position threonine counting from the N-terminus of the GPO is replaced by other amino acid and/or the 420-position aspartic acid counting from the N-terminus of the GPO is replaced by other amino acid.Type: GrantFiled: March 29, 2000Date of Patent: October 16, 2001Assignee: Amano Pharmaceutical Co., Ltd.Inventors: Kenichi Takeuchi, Yoshinao Koide, Yuji Nakanishi, Satoru Suzuki
-
Patent number: 6300102Abstract: The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.Type: GrantFiled: March 10, 1999Date of Patent: October 9, 2001Assignee: Chiron Behring GmbH & Co.Inventors: Bernhard Knapp, Klaus-Dieter Hungerer, Michael Bröker, Bernd-Ulrich von Specht, Horst Domdey
-
Patent number: 6299870Abstract: A new class of polypeptides is disclosed, along with a method for identifying and producing such polypeptides, having the characteristic of being unique to diseased states, particularly tumors and blood-borne malignancies. These new polypeptides are active and will be useful for therapeutic purposes.Type: GrantFiled: February 8, 1999Date of Patent: October 9, 2001Assignee: PBL Biomedical LaboratoriesInventor: Sidney Pestka
-
Patent number: 6300474Abstract: A new class of polypeptides is disclosed, along with a method for identifying and producing such polypeptides, having the characteristic of being unique to diseased states, particularly tumors and blood-borne malignancies. These new polypeptides are active and will be useful for therapeutic purposes.Type: GrantFiled: June 9, 1995Date of Patent: October 9, 2001Assignee: PBL Biomedical LaboratoriesInventor: Sidney Pestka
-
Patent number: 6294164Abstract: A human natural killer cell enhancing factor C and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating viral infections, inflammation, neoplasia and damage from superoxide radicals. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.Type: GrantFiled: September 29, 1999Date of Patent: September 25, 2001Assignee: Human Genome Sciences, Inc.Inventors: Jiar Ni, Guo-Liang Yu, Reiner Gentz, Craig A. Rosen
-
Patent number: 6287812Abstract: A human cytostatin I polypeptide and DNA encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the treatment of cancers, particularly breast cancer, leukemias, and other matastases.Type: GrantFiled: July 28, 1999Date of Patent: September 11, 2001Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Reiner Gentz, Guo-Liang Yu, Craig A. Rosen
-
Patent number: 6288213Abstract: A family of fatty acid transport proteins (FATPs) mediate transport of long chain fatty acids (LCFAs) across cell membranes into cells. These proteins exhibit different expression patterns among the organs of mammals. Nucleic acids encoding FATPs of this family, vectors comprising these nucleic acids, as well as the production of FATP proteins in host cells are described. Also described are methods to test FATPs for fatty acid transport function, and methods to identify inhibitors or enhancers of transport function. The altering of LCFA uptake by administering to the mammal an inhibitor or enhancer of FATP transport function of a FATP in the small intestine can decrease or increase calories available as fats, and can decrease or increase circulating fatty acids. The organ specificity of FATP distribution can be exploited in methods to direct drugs, diagnostic indicators and so forth to an organ such as the heart.Type: GrantFiled: January 14, 1999Date of Patent: September 11, 2001Assignee: Whitehead Institute for Biochemical ResearchInventors: Andreas Stahl, David J. Hirsch, Harvey F. Lodish, Ruth E. Gimeno, Louis A. Tartaglia
-
Patent number: H2021Abstract: The invention provides isolated nucleic acid compounds encoding a novel high molecular weight PBP of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the PBP and a method for identifying compounds that bind and/or inhibit the enzymatic activity of the PBP.Type: GrantFiled: August 19, 1999Date of Patent: May 7, 2002Assignee: Eli Lilly and CompanyInventors: JoAnn Hoskins, Stanley Richard Jaskunas, Jr., Genshi Zhao, Pamela Kay Rockey